Antiviral treatment withdrawal in viremic HCV-positive liver transplant patients: Impact on viral loads, allograft function and morphology

Liver International

Volumn 26, Issue 7, 2006, Pages 811-816

  Kornberg, Arno ^a   Küpper, Bernadett ^a   Tannapfel, Andrea ^b   Thrum, Katharina ^a   Bärthel, Erik ^a   Settmacher, Utz ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Grading; Liver transplantation; Recurrent hepatitis C; Staging

Indexed keywords

AMINOTRANSFERASE; ANTIVIRUS AGENT; AZATHIOPRINE; BILIRUBIN; CYCLOSPORIN A; DACLIZUMAB; EPO; ERYTHROPOIETIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIBAVIRIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; AGED; ALLOGRAFT; ANEMIA; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; CHOLESTASIS; CLINICAL ARTICLE; CONTROLLED STUDY; DETERIORATION; DISEASE COURSE; DRUG WITHDRAWAL; FEMALE; GRAFT RECIPIENT; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALE; MORPHOLOGY; MORTALITY; NEUTROPENIA; NONHUMAN; PATIENT MONITORING; POSTOPERATIVE PERIOD; RECURRENCE RISK; RECURRENT INFECTION; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; VIREMIA; VIRUS LOAD;

ADULT; AGED; ANTIVIRAL AGENTS; DISEASE PROGRESSION; FEMALE; HEPACIVIRUS; HUMANS; INTERFERON ALFA-2B; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RIBAVIRIN; TRANSPLANTATION, HOMOLOGOUS; VIRAL LOAD; VIREMIA;

EID: 33746689687     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2006.01301.x     Document Type: Article

References (21)

1. Gane E. The natural history and outcome of liver transplantation in hepatitis C-virus infected recipients. Liver Transplant 2003; 9 (11): 28-34.
2. Berenguer M. Natural history of recurrent hepatitis C. Liver Transplant 2002; 8: 14-8.
3. Schluger L K, Sheiner P A, Thung S N, et al. Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation. Hepatology 1996; 23 (5): 971-6.
4. Wiesner R H, Sorrell M, Villamil F. Report of the first international liver transplantation society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transplant 2003; 9: 1-9.
5. Ong J P, Younossi Z M, Gramlich T, et al. Interferon-α 2B and ribavirin in severe recurrent cholestatic hepatitis C. Transplantation 2000; 10: 1486-8.
6. Kornberg A, Hommann M, Tannapfel A, et al. Long-term combination of interferon alfa-2b and ribavirin for hepatitis C recurrence in liver transplant patients. Am J Transplant 2001; 1: 350-5.
7. Narayanan M K, Poterucha J, El-Amin O, et al. Treatment of posttransplantationrecurrence of hepatitis C with interferon and ribavirin: Lessons on tolerability and efficacy. Liver Transplant 2002; 8: 623-9.
8. De Vera M E, Smallwood G A, Rosado K, et al. Interferon-alpha and ribavirin for the treatment of recurrent hepatitis C after liver transplantation. Transplantation 2001; 5: 678-86.
9. Samuel D, Bizollon T, Feray C, et al. Interferon-α 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: A randomized study. Gastroenterology 2003; 124: 642-50.
10. Bizollon T, Ahmed S N, Radenne S, et al. Long term histological improvement and clearance of intrahepatic hepatitis C virus following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence. Gut 2003; 52: 283-7.
11. Abdelmalek M F, Firpi R, Soldevila-Pico C, et al. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transplant 2004; 2: 199-207.
12. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-9.
13. Knodell R G, Ishak K G, Black W C, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-5.
14. Stravitz R T, Shiffmann M L, Sanyal A J, et al. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation. Liver Transplant 2004; 10: 850-8.
15. Bizzolon T, Pradat P, Mabrut J Y, et al. Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C. Am J Transplant 2005; 5: 1909-13.
16. Lavezzo B, Franchello A, Smedile A, et al. Treatment of recurrent hepatitis C in liver transplants: Efficacy of a six versus a twelve month course on interferon-alfa 2b with ribavirin. J Hepatol 2002; 37: 247-52.
17. McHutchinson J G, Poynard T. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. Semin Liver Dis 1999; 19 (Suppl.): 57-65.
18. Dickson R C, Caldwell S H, Ishitani M B, et al. Clinical and histologic patterns in early graft failure due to recurrent hepatitis C infection after liver transplantation. Transplantation 1996; 61: 701-5.
19. Rosenberg P, Farrell J, Abraczinskas D, Graeme-Cook F, Dienstag J, Chung R. Rapidly progressive fibrosing cholestatic hepatitis -hepatitis C virus in HIV coinfection. Am J Gastroenterol 2002; 97: 478-83.
20. Triantos C, Samonakis D, Stigliano R, Thalheimer U, Patch D, Burroughs A. Liver transplantation and hepatitis C virus: Systematic review of antiviral therapy. Transplantation 2005; 79: 261-8.
21. Rodriguez-Luna H, Vargas H. Management of hepatitis C virus infection in the setting of liver transplantation. Liver Transplant 2005; 11: 479-89.